Friend or foe? ACE2 inhibitors and GLP-1R agonists in COVID-19 treatment

COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been a pandemic since WHO made the statement on March 11, 2020. The infection is causing a high mortality in old people, especially those with obesity, type 2 diabetes (T2D) or cardiovascular diseases (CVD). Extra...

Descripción completa

Detalles Bibliográficos
Autores principales: Pang, Juan, Liu, Mingyao, Ling, Wenhua, Jin, Tianru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Mini Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785422/
https://www.ncbi.nlm.nih.gov/pubmed/33426364
http://dx.doi.org/10.1016/j.obmed.2020.100312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785422/
https://www.ncbi.nlm.nih.gov/pubmed/33426364
http://dx.doi.org/10.1016/j.obmed.2020.100312

Ejemplares similares